Krane Funds Advisors LLC Zai Lab LTD Transaction History

Krane Funds Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$30.21 - $48.1 $93,348 - $148,629	-3,090 Reduced 8.25%	34,357 $1.27 Million
Q4 2022 Feb 10, 2023	SELL	$22.28 - $38.71 $76,598 - $133,084	-3,438 Reduced 8.41%	37,447 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$34.2 - $51.69 $23,734 - $35,872	694 Added 1.73%	40,885 $1.4 Million
Q2 2022 Aug 11, 2022	BUY	$23.14 - $49.68 $63,449 - $136,222	2,742 Added 7.32%	40,191 $1.39 Million
Q1 2022 May 11, 2022	BUY	$27.77 - $64.4 $92,057 - $213,486	3,315 Added 9.71%	37,449 $1.65 Million
Q4 2021 Feb 10, 2022	SELL	$54.9 - $105.21 $542,851 - $1.04 Million	-9,888 Reduced 22.46%	34,134 $2.15 Million
Q3 2021 Nov 12, 2021	SELL	$105.0 - $178.37 $216,300 - $367,442	-2,060 Reduced 4.47%	44,022 $4.64 Million
Q2 2021 Aug 12, 2021	BUY	$125.11 - $180.0 $216,690 - $311,760	1,732 Added 3.91%	46,082 $8.16 Million
Q1 2021 May 14, 2021	BUY	$126.27 - $191.71 $1.64 Million - $2.49 Million	12,976 Added 41.36%	44,350 $5.92 Million
Q4 2020 Feb 11, 2021	BUY	$81.94 - $135.34 $675,021 - $1.11 Million	8,238 Added 35.61%	31,374 $4.25 Million
Q3 2020 Nov 13, 2020	BUY	$73.3 - $89.48 $577,604 - $705,102	7,880 Added 51.65%	23,136 $1.92 Million
Q2 2020 Aug 10, 2020	BUY	$48.82 - $82.53 $408,428 - $690,445	8,366 Added 121.42%	15,256 $1.25 Million
Q1 2020 May 12, 2020	BUY	$39.1 - $62.9 $265,489 - $427,091	6,790 Added 6790.0%	6,890 $355,000
Q4 2019 Feb 10, 2020	SELL	$29.79 - $43.06 $1,638 - $2,368	-55 Reduced 35.48%	100 $4,000
Q2 2019 Aug 13, 2019	BUY	$25.73 - $35.79 $3,988 - $5,547	155 New	155 $5,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.59B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Krane Funds Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Krane Funds Advisors LLC with notifications on news.